Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases

Visser, 2009, Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature, Ann Rheum Dis, 68, 1094, 10.1136/ard.2008.092668 Mouterde, 2011, Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review, Joint Bone Spine, 78, 587, 10.1016/j.jbspin.2011.01.010 Ramiro, 2014, Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Ann Rheum Dis, 73, 529, 10.1136/annrheumdis-2013-204575 Tornero Molina, 2015, Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration routes, Reumatol Clin, 11, 3, 10.1016/j.reuma.2014.02.012 Sanmarti, 2015, 2014 update of the consensus statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis, Reumatol Clin, 11, 279 Smolen, 2014, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum Dis, 73, 492, 10.1136/annrheumdis-2013-204573 Katchamart, 2009, Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis, Ann Rheum Dis, 68, 1105, 10.1136/ard.2008.099861 Wegrzyn, 2004, Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis, Ann Rheum Dis, 63, 1232, 10.1136/ard.2003.011593 Branco, 2016, Utilization of subcutaneous methotrexate in rheumatoid arthritis patients after failure or intolerance to oral methotrexate: a multicenter cohort study, Adv Ther, 10.1007/s12325-015-0276-3 Yadlapati, 2016, Inadequate response or intolerability to oral methotrexate: is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?, Rheumatol Int, 36, 627, 10.1007/s00296-016-3447-x Fitzpatrick, 2013, Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate, Clin Rheumatol, 32, 1605, 10.1007/s10067-013-2318-z Hassanzadeh, 2012, Subcutaneous methotrexate to cut costs?, J Rheumatol, 39, 1764, 10.3899/jrheum.120091 Mainman, 2010, When should we use parenteral methotrexate?, Clin Rheumatol, 29, 1093, 10.1007/s10067-010-1500-9 Black, 1999, Consensus development methods: a review of best practice in creating clinical guidelines, J Health Serv Res Policy, 4, 236, 10.1177/135581969900400410 CEBM, 2013 Schiff, 2014, Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15mg may be overcome with subcutaneous administration, Ann Rheum Dis, 73, 1549, 10.1136/annrheumdis-2014-205228 Hamilton, 1997, Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis, Br J Rheumatol, 36, 86, 10.1093/rheumatology/36.1.86 Hoekstra, 2004, Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis, J Rheumatol, 31, 645 Jundt, 1993, A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing, J Rheumatol, 20, 1845 Brooks, 1990, Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis, Arthritis Rheum, 33, 91, 10.1002/art.1780330112 Lafforgue, 1995, Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis, J Rheumatol, 22, 844 Oguey, 1992, Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis, Arthritis Rheum, 35, 611, 10.1002/art.1780350603 Braun, 2008, Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial, Arthritis Rheum, 58, 73, 10.1002/art.23144 Islam, 2013, Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis, Mymensingh Med J, 22, 483 Bingham, 2003, Parenteral methotrexate should be given before biological therapy, Rheumatology (Oxf), 42, 1009, 10.1093/rheumatology/keg246 Borman, 2014, Subcutaneous (sc) methotrexate (MTX) is better and well-tolerable than oral MTX in rheumatoid arthritis patients, switched from oral to sc administration due to gastrointestinal side effects, Open Rheumatol J, 8, 18, 10.2174/1874312901408010018 Griffin, 2004, Parenteral methotrexate should be given before biological therapy, Rheumatology (Oxf), 43, 678, 10.1093/rheumatology/keh110 Stamp, 2011, Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis, J Rheumatol, 38, 2540, 10.3899/jrheum.110481 Arthur, 1999, Safety of self-injection of gold and methotrexate, J Rheumatol, 26, 302 Freundlich, 2014, Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations, J Clin Rheumatol, 20, 256, 10.1097/RHU.0000000000000117 Bharadwaj, 2008, Use of parenteral methotrexate significantly reduces the need for biological therapy, Rheumatology (Oxf), 47, 222, 10.1093/rheumatology/kem306 Muller, 2015, Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen cohort, Semin Arthritis Rheum, 45, 28, 10.1016/j.semarthrit.2015.02.009 Striesow, 2012, Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation, Ther Adv Musculoskelet Dis, 4, 3, 10.1177/1759720X11431004 Thornton, 2008, Comment on: Use of parenteral methotrexate significantly reduces the need for biological therapy, Rheumatology (Oxf), 47, 1438, 10.1093/rheumatology/ken250 Scott, 2014, Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study, Scand J Rheumatol, 43, 470, 10.3109/03009742.2014.910312 Rutkowska-Sak, 2009, Oral vs subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects, Reumatologia, 47, 207 Thompson, 1984, A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis, J Rheumatol, 11, 760 Muller-Ladner, 2010, Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritis, Open Rheumatol J, 4, 15, 10.2174/1874312901004010015 Demary, 2014, Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience, Patient Prefer Adherence, 8, 1061 Burbage, 2001, Intramuscular methotrexate in inflammatory rheumatic disease, Ann Rheum Dis, 60, 1156, 10.1136/ard.60.12.1156 Hameed, 2010, Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis, Int J Rheum Dis, 13, e83, 10.1111/j.1756-185X.2010.01482.x Rau, 1997, Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients, Br J Rheumatol, 36, 345, 10.1093/rheumatology/36.3.345 Michaels, 1982, Weekly intravenous methotrexate in the treatment of rheumatoid arthritis, Arthritis Rheum, 25, 339, 10.1002/art.1780250312 Bakker, 2010, Are switches from oral to subcutaneous methotrexate or addition of cyclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A posthoc analysis of the CAMERA study, Ann Rheum Dis, 69, 1849, 10.1136/ard.2009.124065 Lambert, 2004, Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial, Arthritis Rheum, 50, 364, 10.1002/art.20167 O’Dell, 2015, Underuse of methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) in the United States (US): results of a claims analysis, Arthritis Rheum, 67, 2368 Schiff, 2015, Oral to subcutaneous methotrexate dose-conversion strategies in the treatment of rheumatoid arthritis, Arthritis Rheum, 67, 3831 Crespo, 2010, [Pharmacoeconomic analysis of metoject (R) in the treatment of rheumatoid arthritis in Spain], Reumatol Clin, 6, 203, 10.1016/j.reuma.2009.11.001 Linde, 2006, Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate, Scand J Rheumatol, 35, 102, 10.1080/03009740500343294 Visser, 2009, Ann Rheum Dis, 68, 1086, 10.1136/ard.2008.094474 Todoerti, 2013, Systematic review of 2008–2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis, Reumatismo, 65, 207, 10.4081/reumatismo.2013.207 Katchamart, 2010, Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis, J Rheumatol, 37, 1422, 10.3899/jrheum.090978